H.C. Wainwright analyst Raghuram Selvaraju raised his price target for BioSpecifics Technologies to $72 after the company announced positive top-line data from the Phase 1 trial of Collagenase Clostridium Histolyticum for the treatment of uterine fibroids. The open-label study met the primary endpoint of safety and tolerability with no observed clinically significant adverse reactions, says the analyst. Further, he finds it important that statistically significant reductions in collagen content were observed as compared to control fibroids with a median reduction of 39%. Selvaraju reiterates a Buy rating on the shares.